EN DE
STOCK COMPARISON

Zhejiang Hisoar Pharmaceutical Co vs PT Amman Mineral Internasional: Fair Value & Quality

Both stocks run through our valuation models. Here is how Zhejiang Hisoar Pharmaceutical Co (002099) and PT Amman Mineral Internasional (AMMN) compare, as of Sep 5, 2026.

As of Sep 5, 2026, Fair Value Calculator sees PT Amman Mineral Internasional as the less overvalued of the two: Zhejiang Hisoar Pharmaceutical Co trades at ¥5.41 versus a fair value of ¥1.20 (-78%), while PT Amman Mineral Internasional trades at IDR 4,390 versus IDR 1,021 (-77%).
Zhejiang Hisoar Pharmaceutical Co
002099.SHE · CNY · Health Care
-78%
upside to fair value
overvalued
Price¥5.41
Fair Value¥1.20
Quality51/100
PT Amman Mineral Internasional
AMMN.JK · IDR · Materials
-77%
upside to fair value
overvalued
PriceIDR 4,390
Fair ValueIDR 1,021
Quality26/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Zhejiang Hisoar Pharmaceutical CoPT Amman Mineral Internasional
Valuation
—P/E (TTM)24.0×
0.68×P/S (TTM)9.58×
0.25×P/B4.76×
—EV/EBITDA20.7×
−77.8%Fair value upside−76.7%
0.3%Dividend yield—
Profitability
3%Operating margin39%
—EBIT margin trend (5Y)1.38×
-2%Return on equity10%
-1%Return on assets5%
Growth
0%Revenue growth (YoY)379%
-11.7%Avg. growth/yr (3Y)-13.6%
-5.5%Avg. growth/yr (5Y)12.7%
—Value creation/yr+0.9%
Balance & size
—Interest coverage (EBIT/interest)1.7×
0.03×Debt / equity1.10×
$1BMarket cap$25B
weakGrowth qualityweak
Valuation multiples (P/E, P/S, P/B, EV/EBITDA) are shown but not scored here: the two companies sit in different sectors, and multiples only compare fairly between similar business models. PEG stays scored, as it relates the P/E to growth.

PT Amman Mineral Internasional leads: 2 to 4 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Zhejiang Hisoar Pharmaceutical Coof which business quality 49 · market factors 33 PT Amman Mineral Internasionalof which business quality 25 · market factors 32
ProfitabilityMargins and returns on capital today
9
25
Quality GrowthAre margins and returns improving?
66
5
CashflowEarnings quality: real cash, not paper profit
5
0
Fin. StrengthBalance sheet, leverage, solvency risk
83
46
InvestmentDisciplined investing over empire-building
96
9
Low VolatilityCalm price path (market factor)
65
50
MomentumPrice trend over the last 3–12 months (market factor)
22
31
52W MomentumDistance to the 52-week high (market factor)
15
13
Net IssuanceBuybacks instead of dilution
67
65

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyZhejiang Hisoar Pharmaceutical CoPrice ¥5.41PT Amman Mineral InternasionalPrice IDR 4,390
DCF Models-59%below the price¥2.21n/a
Earnings-Basedn/a-88%below the priceIDR 511
Dividend Discount-96%below the price¥0.20n/a
Multiples-33%below the price¥3.61-77%below the priceIDR 1,021
Asset-Based-61%below the price¥2.09-81%below the priceIDR 851
Economic Profitn/a-83%below the priceIDR 766
Growth Earningsn/a-84%below the priceIDR 681
Minimum-96%below the price¥0.20-88%below the priceIDR 511
Maximum-33%below the price¥3.61-77%below the priceIDR 1,021
Median-60%below the price¥2.15-83%below the priceIDR 766
Geometric mean-75%below the price¥1.35-83%below the priceIDR 746

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Zhejiang Hisoar Pharmaceutical Co: 5 of 5 models see the stock below the current price.

PT Amman Mineral Internasional: 11 of 11 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Zhejiang Hisoar Pharmaceutical Co
Bear ¥1.08Fair Value ¥1.20Bull ¥1.39
¥5.41 = current price (white tick)
PT Amman Mineral Internasional
Bear IDR 766Fair Value IDR 1,021Bull IDR 1,277
IDR 4,390 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Zhejiang Hisoar Pharmaceutical Co · Health Care

Quality score51 · below median
Fair value upside-78% · bottom 25%

PT Amman Mineral Internasional · Materials

Quality score26 · bottom 25%
Fair value upside-77% · bottom 25%

Bottom line

As of Sep 5, 2026, Fair Value Calculator sees PT Amman Mineral Internasional as the less overvalued of the two: Zhejiang Hisoar Pharmaceutical Co trades at ¥5.41 versus a fair value of ¥1.20 (-78%), while PT Amman Mineral Internasional trades at IDR 4,390 versus IDR 1,021 (-77%).

Zhejiang Hisoar Pharmaceutical Co has the higher quality score (51/100).

See the full analysis →
Zhejiang Hisoar Pharmaceutical Co · PT Amman Mineral Internasional

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Zhejiang Hisoar Pharmaceutical Co

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupMerck & Company vs UnitedHealth Group

Related to PT Amman Mineral Internasional

Alphabet Inc Class C vs Verizon CommunicationsAlphabet Inc Class C vs At&tAlphabet Inc Class C vs NetEaseAmazon.com vs PDD Holdings
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.